A Swedish innovative, patented and unique cancer
Potentially effective on all cancer types with solid tumours draining through the lymphatic system (>90 % of global cancer incidence)
Based on the patient’s own immune system
Very promising, early clinical results
Photo: Thomas Lundquist
No significant side effects
Autologous treatment
113 patients treated so far (October-09)
Broad potential product portfolio
Single 1st line treatment
Combination treatment w. standard chemotherapy
Adjuvant treatment